Status:

COMPLETED

Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies with Early Access Authorization in Immunocompromised Patients. a Prospective Cohort.

Lead Sponsor:

ANRS, Emerging Infectious Diseases

Conditions:

COVID-19

Immunocompromised Host

Eligibility:

All Genders

18+ years

Brief Summary

This prospective cohort of patients, receiving pre exposure prophylaxis by Anti-SARS-CoV-2 Monoclonal Antibodies, is designed to evaluate the treatment protection against SARS-CoV-2 variants of concer...

Eligibility Criteria

Inclusion

  • Adults (18 years-old or more)
  • Patient who received the first administration of Evusheld at 300 mg for less than 4 months and should receive a second dose, according to French recommendations OR Patient scheduled to receive or having received less than a month ago an injection of anti-SARS-CoV-2 monoclonal antibodies, as pre-exposure prophylaxis at 600 mg, according to the French SARS-CoV-2 RT recommendations
  • qPCR negative at baseline
  • SARS-CoV-2 RT-qPCR Negative at inclusion
  • Patients who remain seronegative after a complete COVID-19 vaccination schedule
  • Immunocompromised patients :
  • Hemopathy : chronic lymphoid leukemia, non hodgkin's lymphoma, HSCT Transplant recipient : kidney, liver, lungs Patients receiving anti CD20 or others immunosuppressor
  • Life expectancy \> 3 months
  • Social security affiliation
  • Lack of a legal protection measure
  • Signed informed consent

Exclusion

  • Participation to another clinical study
  • State medical aid
  • Ongoing or scheduled plasmapheresis or immunoadsorption
  • Pregnant / lactating woman
  • Patient whose isolation period is underway following contact with a confirmed case of SARS-CoV2 infection
  • Hypersensitivity to one of the active substances or to one of the excipients

Key Trial Info

Start Date :

January 26 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 31 2024

Estimated Enrollment :

149 Patients enrolled

Trial Details

Trial ID

NCT05216588

Start Date

January 26 2022

End Date

October 31 2024

Last Update

January 29 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpital Avicenne

Bobigny, France, 93000